Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free CDTTW Stock Alerts

Conduit Pharmaceuticals (CDTTW) Competitors

$0.0055 0.00 (-1.78%)
Closing price 10/14/2026 11:53 AM Eastern
Extended Trading
$0.01 +0.00 (+39.24%)
As of 10/14/2026 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CDTTW vs. SXTPW, BFRIW, CALA, CINGW, and CLVR

Should you buy Conduit Pharmaceuticals stock or one of its competitors? Conduit Pharmaceuticals's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Calithera Biosciences (CALA), Cingulate (CINGW), and Clever Leaves (CLVR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Conduit Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Conduit Pharmaceuticals. Conduit Pharmaceuticals' average media sentiment score of 1.79 beat 60 Degrees Pharmaceuticals' score of 1.39 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Positive
Conduit Pharmaceuticals Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

Summary

60 Degrees Pharmaceuticals beats Conduit Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

How does Conduit Pharmaceuticals compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

In the previous week, Biofrontera had 1 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for Conduit Pharmaceuticals. Conduit Pharmaceuticals' average media sentiment score of 1.79 beat Biofrontera's score of 0.91 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Positive
Conduit Pharmaceuticals Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Biofrontera beats Conduit Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

How does Conduit Pharmaceuticals compare to Calithera Biosciences?

Conduit Pharmaceuticals (NASDAQ:CDTTW) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conduit PharmaceuticalsN/AN/AN/AN/AN/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

In the previous week, Conduit Pharmaceuticals and Conduit Pharmaceuticals both had 1 articles in the media. Conduit Pharmaceuticals' average media sentiment score of 1.79 beat Calithera Biosciences' score of 0.67 indicating that Conduit Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Conduit Pharmaceuticals Very Positive
Calithera Biosciences Positive

Company Net Margins Return on Equity Return on Assets
Conduit PharmaceuticalsN/A N/A N/A
Calithera Biosciences N/A N/A N/A

Summary

Conduit Pharmaceuticals beats Calithera Biosciences on 1 of the 1 factors compared between the two stocks.

How does Conduit Pharmaceuticals compare to Cingulate?

Conduit Pharmaceuticals (NASDAQ:CDTTW) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Company Net Margins Return on Equity Return on Assets
Conduit PharmaceuticalsN/A N/A N/A
Cingulate N/A N/A N/A

In the previous week, Cingulate had 1 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 2 mentions for Cingulate and 1 mentions for Conduit Pharmaceuticals. Conduit Pharmaceuticals' average media sentiment score of 1.79 beat Cingulate's score of 1.41 indicating that Conduit Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Conduit Pharmaceuticals Very Positive
Cingulate Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conduit PharmaceuticalsN/AN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Summary

Conduit Pharmaceuticals and Cingulate tied by winning 1 of the 2 factors compared between the two stocks.

How does Conduit Pharmaceuticals compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

In the previous week, Conduit Pharmaceuticals had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for Conduit Pharmaceuticals and 0 mentions for Clever Leaves. Conduit Pharmaceuticals' average media sentiment score of 1.79 beat Clever Leaves' score of 0.00 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Clever Leaves Neutral
Conduit Pharmaceuticals Very Positive

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Conduit Pharmaceuticals has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$7.56N/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Clever Leaves beats Conduit Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

Get Conduit Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDTTW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDTTW vs. The Competition

Export
MetricConduit PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.14B$7.19B$13.18B
Dividend YieldN/A2.63%2.52%19.60%
P/E RatioN/A658.79211.4219.26
Price / SalesN/A751.30565.6077.58
Price / CashN/A84.0876.6852.75
Price / BookN/A9.1510.515.92
Net IncomeN/A$2.82B$3.50B$380.90M
7 Day PerformanceN/A-3.79%-3.49%-3.85%
1 Month PerformanceN/A-7.63%-7.76%-6.37%
1 Year PerformanceN/A-6.12%0.82%-6.01%

Conduit Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CDTTW
Conduit Pharmaceuticals
N/A$0.01
-1.8%		N/A-68.0%$0.00N/AN/A4
SXTPW
60 Degrees Pharmaceuticals
N/A$0.02
flat		N/A-45.0%$0.00$1.11MN/A3
BFRIW
Biofrontera
N/A$0.01
-21.0%		N/A-94.4%$0.00$46.18MN/A94
CALA
Calithera Biosciences
N/A$0.00
flat		N/A+50.0%$0.00N/AN/A60
CINGW
Cingulate
N/A$0.01
flat		N/A-86.6%$0.00N/AN/A14

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CDTTW) was last updated on 10/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel